Approach to the patient with transplantation-related bone loss

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 5, 2009, Pages 1483-1490

  Ebeling, Peter R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CYCLOSPORIN A; DACLIZUMAB; GLUCOCORTICOID; IBANDRONIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; PLACEBO; RAPAMYCIN; RISEDRONIC ACID; TACROLIMUS; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITOMETRY; BONE MARROW TRANSPLANTATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; FRACTURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; HYPERPARATHYROIDISM; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; X RAY; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE DENSITY; CASE REPORT; FEMALE; GRAFT VERSUS HOST REACTION; LIVER TRANSPLANTATION; PHOTON ABSORPTIOMETRY; TRANSPLANTATION;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; OSTEOPOROSIS; TRANSPLANTATION;

EID: 66149146642     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0205     Document Type: Article

References (59)

1. Ebeling PR 2008 Transplantation osteoporosis. In: Rosen CJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Chap 61. Washington, DC: American Society for Bone Mineral Research; 279-285
2. Cohen A, Sambrook P, Shane E 2004 Management of bone loss after organ transplantation. J Bone Miner Res 19:1919-1932
3. Cohen A, Shane E 2003 Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14:617-630 (Pubitemid 41490345)
4. Keilholz U, Max R, Scheibenbogen C, Wüster C, Körbling M, Haas R 1997 Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation. Cancer 79:1617-1622 (Pubitemid 27154797)
5. Tauchmanovà L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, Rotoli B, Colao A 2002 High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 95:1076-1084
6. Välimäki MJ, Kinnunen K, Volin L, Tähtelä R, Löyttyniemi E, Laitinen K, Mäkelä P, Keto P, Ruutu T 1999 A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23:355-361 (Pubitemid 29105959)
7. Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Välimäki MJ 2005 Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 90:3877-3885 (Pubitemid 41058146)
8. Schulte C, Beelen DW, Schaefer UW, Mann K 2000 Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 11:344-353 (Pubitemid 30417188)
9. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS 2000 Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200-2205
10. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C 2000 Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396-399 (Pubitemid 30429887)
11. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, Kestenbaum BR, Stehman-Breen C 2002 Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288:3014-3018 (Pubitemid 35471163)
12. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ 1997 Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. Am J Med 103:197-207 (Pubitemid 27413402)
13. Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martinez de Osaba MJ, Ordi J, Rimola A, Rodés J, Muñoz-Gómez J 2001 Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484-492 (Pubitemid 32607092)
14. Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W 2005 Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 11:960-966 (Pubitemid 41122454)
15. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE 2001 High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 69:321-326 (Pubitemid 34056794)
16. Tschopp O, Boehler A, Speich R, Weder W, Seifert B, Russi EW, Schmid C 2002 Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant 2:167-172 (Pubitemid 36306796)
17. Defranco DJ, Lian JB, Glowacki J 1992 Differential effects of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats. Endocrinology 131:114-121
18. Epstein S 1996 Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J Bone Miner Res 11:1-7 (Pubitemid 26026737)
19. Ponticelli C, Aroldi A 2001 Osteoporosis after organ transplantation. Lancet 357:1623 (Pubitemid 32488839)
20. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR 1995 Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 9:20-24
21. Stempfle HU, Werner C, Echtler S, Assum T, Meiser B, Angermann CE, Theisen K, Gärtner R 1998 Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc 30:1132-1133 (Pubitemid 28309511)
22. Park KM, Hay JE, Lee SG, Lee YJ, Wiesner RH, Porayko MK, Krom RA 1996 Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc 28:1738-1740
23. Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y 2001 Osteoporosis after organ transplantation. Lancet 357:1623 (Pubitemid 32488839)
24. Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martínez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gómez J 2001 Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 68:83-86 (Pubitemid 32289863)
25. Singha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J, Xiao G 2008 Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 103:434-446
26. Banfi A, Podestà M, Fazzuoli L, Sertoli MR, Venturini M, Santini G, Cancedda R, Quarto R 2001 High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 92:2419-2428 (Pubitemid 33029088)
27. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon KH, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim CC 2002 The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 87:329-335 (Pubitemid 34084710)
28. Chan GK, Miao D, Deckelbaum R, Bolivar I, Karaplis A, Goltzman D 2003 Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T mesenchymal cells. Endocrinology 144:5511-5520 (Pubitemid 37476081)
29. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP 1999 Mechanism of bone loss following allogeneic and autologous hematopoeitic stem cell transplantation. J Bone Miner Res 14:342-350 (Pubitemid 29106711)
30. Ebeling PR 2005 Bone disease after bone marrow transplantation. In: Compston J, Shane E, eds. Bone disease of organ transplantation. Chap 19. Atlanta: Elsevier, Academic Press; 339-352
31. Lee WY, Kang MI, Baek KH, Oh ES, Oh KW, Lee KW, Kim SW, Kim CC 2002 The skeletal site-differential changes in bone mineral density following bone marrow transplantation: 3-year prospective study. J Korean Med Sci 17:749-754
32. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S, Bearcroft PW, Milligan TP, Price CP, Marcus RE, Compston JE 2003 Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 121:462-468 (Pubitemid 36628338)
33. Ebeling PR 2005 Is defective osteoblast function responsible for bone loss from the proximal femur despite pamidronate therapy? J Clin Endocrinol Metab 90:4414-4416
34. Tauchmanovà L, Selleri C, Esposito M, Di Somma C, Orio Jr F, Bifulco G, Palomba S, Lombardi G, Rotoli B, Colao A 2003 Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 14:1013-1019 (Pubitemid 40834215)
35. Tauchmanovà L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, Selleri C 2005 Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 90:627-634 (Pubitemid 40279172)
36. Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling PR 2006 Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 91:3835-3843 (Pubitemid 44536852)
37. D'Souza AB, Grigg AP, Szer J, Ebeling PR 2006 Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Int Med J 36:600-603 (Pubitemid 44179835)
38. Chae YS, Kim JG, Moon JH, Kim SN, Lee SJ, Kim YJ, Sohn SK 12 January 2009 Pilot study on the use of zoledronic acid to prevent bone loss in Allo-SCT recipients. Bone Marrow Transplant 10.1038/bmt.2008.414
39. Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K 2008 Abnormal bone and mineral metabolism in kidney transplant patients - a review. Am J Nephrol 28:246-253
40. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, Langman CB, Salinger MH, Sprague SM 1999 Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 14:456-463 (Pubitemid 29106723)
41. Sprague SM, Josephson MA 2004 Bone disease after kidney transplantation. Sem Nephrol 24:82-90 (Pubitemid 38141849)
42. Palmer SC, McGregor DO, Strippoli GFM 2007 Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007:CD005015. Chichester, UK: John Wiley & Sons, Ltd.
43. Miller PD 2005 Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 3:5-12
44. Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, Mancini D, Addesso V, Michler RE, Factor-Litvak P 1996 Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 81:1740-1746 (Pubitemid 26152456)
45. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R 2001 Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357:342-347 (Pubitemid 32128540)
46. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J 2000 Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15:1818-1824
47. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D 2004 Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776 (Pubitemid 38209646)
48. Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, Mancini D, Shane E 2006 Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation 81:686-691
49. Braith RW, Magyari PM, Fulton MN, Lisor CF, Vogel SE, Hill JA, Aranda Jr JM 2006 Comparison of calcitonin versus calcitonin and resistance exercise as prophylaxis for osteoporosis in heart transplant recipients. Transplantation 81:1191-1195 (Pubitemid 43754672)
50. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE 2002 Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37:93-100 (Pubitemid 34713060)
51. Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore CE 2007 Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int 27:251-256 (Pubitemid 46088254)
52. Hommann M, Abendroth K, Lehmann G, Patzer N, Kornberg A, Voigt R, Seifert S, Hein G, Scheele J 2002 Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc 34:2296-2298 (Pubitemid 35299752)
53. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW 2006 Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239-248 (Pubitemid 46768206)
54. Atamaz F, Hepguler S, Karasu Z, Kilic M, Tokat Y 2006 The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc 38:1448-1452 (Pubitemid 43912724)
55. Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C, Schulman LL 1999 Bone loss and fracture after lung transplantation. Transplantation 68:220-227 (Pubitemid 29360280)
56. Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, Ontjes DA 2000 Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 162:941-946
57. Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R 2000 Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 19:736-743
58. Braith RW, Conner JA, Fulton MN, Lisor CF, Casey DP, Howe KS, Baz MA 2007 Comparison of alendronate vs. alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J Heart Lung Transplant 26:132-137 (Pubitemid 46136030)
59. Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S, Nuttall ME 2006 Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 39:1361-1372